Downloads: 11 | Views: 305 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1

Analysis Study Research Paper | Pharmaceutical Science | India | Volume 12 Issue 6, June 2023 | Popularity: 5.2 / 10

Rate This Article!      

Synthesis Evaluation Using Cell Lines of Analogues Indole-Based Agents as Tubulin Inhibitors

Divya .S, Ayushi Khurana

Abstract: Combretastatin is a natural product and atubulin inhibitor that is recognised from other synthetic, natural occurring and semi-synthetic tubulin inhibitors discovered in the past. Many pro-drugs have undergone through clinical testing as vascular targeting medicines, such as combretastatin as Vascular Disrupting Agents developed by their improved selectivity towards endothelial cells as well as their innate capacity to swiftly cause vascular shutdown and stop the tumour development. The molecular target of combretastatin and the big majority of their tubulin, synthetic variants, is well known. Disruption of the microtubule by combretastatin that targets it decreases cell growth and causes mitotic spindles in the G2-M phase of the cell cycle. Combretastatin A-4 inhibits tubulin polymerization by engaging with the microtubule’s colchicine binding site and has shown significant lethal impact in a broad range of preclinical tumour types. By altering the dynamics of tubulin, such as depolymerization and polymerization combretastatin has an impact. Numerous analogues made from combretastatin have also been created due to their structural simplicity and have shown strong promise as inhibitors of tubulin polymerization. In this review, the pharmacological properties of combretastatin as a category of effective antimitotic anticancer agents are presented anddiscussed.

Keywords: Combretastatins analogues, tubulin inhibitors, anticancer

Edition: Volume 12 Issue 6, June 2023

Pages: 2837 - 2843

DOI: https://www.doi.org/10.21275/SR23628132206

Make Sure to Disable the Pop-Up Blocker of Web Browser

Click to Cite this Article